Invenomic Capital Exits $24M Haemonetics Stake Amid MedTech Underperformance
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker. The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.